Exelixis
EXEL
#1574
Rank
A$17.43 B
Marketcap
$62.30
Share price
2.76%
Change (1 day)
84.77%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): A$1.03 Billion

According to Exelixis's latest financial reports the company's current earnings are A$2.16 Billion. , an increase over its 2023 earnings that were of A$0.41 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 A$1.09 B164.69%
2023 A$0.41 B9.89%
2022 A$0.37 B-20.33%
2021 A$0.47 B124.82%
2020 A$0.21 B-67.14%
2019 A$0.64 B-11.94%
2018 A$0.72 B185.09%
2017 A$0.25 B-325.82%
2016 -A$0.12 Billion-58.12%
2015 -A$0.27 Billion-37.61%
2014 -A$0.44 Billion9.75%
2013 -A$0.4 Billion65.96%
2012 -A$0.24 Billion-291.63%
2011 A$0.12 B-195.59%
2010 -A$0.13 Billion-42.17%
2009 -A$0.23 Billion-18.98%
2008 -A$0.28 Billion-6.99%
2007 -A$0.3 Billion46.3%
2006 -A$0.21 Billion33.25%
2005 -A$0.16 Billion-30.92%
2004 -A$0.23 Billion44.29%
2003 -A$0.16 Billion12.86%
2002 -A$0.14 Billion22.79%
2001 -A$0.12 Billion60.14%
2000 -A$69.02 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
A$6.71 B 511.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$12.78 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
A$24.10 B 2,096.61%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$13.5 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
A$7.42 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
A$28.08 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
A$11.17 B 918.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$72.16 Million-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$46.76 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA